Opaleye Management Inc. — 13F Holdings

2026 Q2  ·  67 Positions

2026 Q2 Portfolio Activity

In 2026 Q2, Opaleye Management Inc. maintained a portfolio of 67 distinct positions. The most significant new addition was IMMIX BIOPHARMA INC, now representing 2.19% of the total fund value. They heavily accumulated shares in DISC MEDICINE INC, increasing the position by 103.1%. The fund also reduced its exposure to CRESCENT BIOPHARMA INC. by 95.0%.
Position History hover any row below to update
Loading…
PCA Score Concentration Risk
Risk ENB
Total Positions
67
Quarter
2026 Q2
Top Holding
LQDA (17.7%)
Top 10 Concentration
64.8%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-50 of 67

Opaleye Management Inc. Full Holdings List — 2026 Q2

Stock History Sector / Type Port % Prev % Rank / Prev Conviction
Freshness
Change % Change Influence Shares Mkt Value Avg Cost Price Held 1st Owned Source Source Date Date Reported
LQDA
LIQUIDIA CORPOR...
Healthcare 17.67% 11.70% #1 1
Prev: #2
6.5
-97,500 -3.8%
P
S
2,447,500 $195,139,175
$11.62 +539.8%
$79.73 -6.8%
2019 Q1 13F Filing 2026-06-30 2026-08-14
ETON
ETON PHARMACEUT...
Healthcare 9.38% 9.30% #2 1
Prev: #3
6.3
no change no change
P
S
2,860,000 $103,532,000 2018 Q4 13F Filing 2026-06-30 2026-08-14
HROW
HARROW INC
Healthcare 9.23% 13.15% #3 2
Prev: #1
5.2
-432,230 -15.3%
P
S
2,400,000 $101,928,000 2020 Q2 13F Filing 2026-06-30 2026-08-14
IRON
DISC MEDICINE I...
Healthcare 5.66% 3.55% #4 3
Prev: #7
5.8
434,000 103.1%
P
S
855,000 $62,534,700 2025 Q1 13F Filing 2026-06-30 2026-08-14
URGN
UROGEN PHARMA L...
Healthcare 4.80% 3.39% #5 3
Prev: #8
2.9
9,996 0.7%
P
S
1,439,996 $52,991,853 2022 Q2 13F Filing 2026-06-30 2026-08-14
APGE
APOGEE THERAPEU...
Healthcare 4.69% 4.32% #6
Prev: #6
2.9
no change no change
P
S
390,000 $51,764,700 2025 Q3 13F Filing 2026-06-30 2026-08-14
MGTX
MEIRAGTX HLDGS ...
Healthcare 4.34% 2.42% #7 6
Prev: #13
4.7
1,426,741 67.2%
P
S
3,550,000 $47,960,500 2022 Q3 13F Filing 2026-06-30 2026-08-14
SLGL
SOL-GEL TECHNOL...
Healthcare 3.36% 5.22% #8 4
Prev: #4
2.3
no change no change
P
S
500,000 $37,070,000 2025 Q3 13F Filing 2026-06-30 2026-08-14
RZLT
REZOLUTE INC
Healthcare 2.97% 2.53% #9 3
Prev: #12
2.2
no change no change
P
S
6,300,000 $32,760,000 2024 Q3 13F Filing 2026-06-30 2026-08-14
TGTX
TG THERAPEUTICS...
Healthcare 2.66% 2.34% #10 4
Prev: #14
2.1
no change no change
P
S
535,000 $29,392,900 2015 Q3 13F Filing 2026-06-30 2026-08-14
IMMX
IMMIX BIOPHARMA...
Healthcare 2.19% #11
Prev: #—
4.4
2,345,000
NEW
2,345,000 $24,176,950 2026 Q2 13F Filing 2026-06-30 2026-08-14
N/A
CRESCENT BIOPHA...
Unknown 2.15% 3.18% #12 3
Prev: #9
1.4
6,736 0.5%
P
S
1,319,351 $23,748,318 13F Filing 2026-06-30 2026-08-14
STOK
STOKE THERAPEUT...
Healthcare 2.07% 3.00% #13 3
Prev: #10
1.8
no change no change
P
S
700,000 $22,904,000 2024 Q4 13F Filing 2026-06-30 2026-08-14
ACOG
ALPHA COGNITION...
Healthcare 1.89% 1.85% #14 3
Prev: #17
2.8
333,517 13.0%
P
S
2,895,467 $20,905,272 2025 Q3 13F Filing 2026-06-30 2026-08-14
EWTX
EDGEWISE THERAP...
Healthcare 1.84% 2.07% #15 1
Prev: #16
1.7
no change no change
P
S
500,000 $20,315,000 2022 Q1 13F Filing 2026-06-30 2026-08-14
RVMD
REVOLUTION MEDI...
Healthcare 1.70% 1.28% #16 6
Prev: #22
1.7
no change no change
P
S
100,000 $18,728,000 2025 Q2 13F Filing 2026-06-30 2026-08-14
GLUE
MONTE ROSA THER...
Healthcare 1.63% #17
Prev: #—
4.2
745,000
NEW
745,000 $18,029,000 2026 Q2 13F Filing 2026-06-30 2026-08-14
ALMS
ALUMIS INC
Healthcare 1.40% 1.60% #18 1
Prev: #19
1.6
no change no change
P
S
550,000 $15,477,000 2025 Q2 13F Filing 2026-06-30 2026-08-14
CDXS
CODEXIS INC
Healthcare 1.39% 1.46% #19 1
Prev: #20
1.6
no change no change
P
S
6,785,000 $15,334,100 2014 Q1 13F Filing 2026-06-30 2026-08-14
REPL
REPLIMUNE GROUP...
Healthcare 1.39% #20
Prev: #—
4.1
1,384,993
NEW
1,384,993 $15,331,873 2026 Q2 13F Filing 2026-06-30 2026-08-14
XOMA
XOMA ROYALTY CO...
Healthcare 1.30% 1.24% #21 2
Prev: #23
2.5
38,374 12.8%
P
S
338,374 $14,380,895 2017 Q1 13F Filing 2026-06-30 2026-08-14
MBX
MBX BIOSCIENCES...
Healthcare 1.30% 1.02% #22 3
Prev: #25
1.5
no change no change
P
S
260,000 $14,352,000 2025 Q1 13F Filing 2026-06-30 2026-08-14
RYTM
RHYTHM PHARMACE...
Healthcare 1.23% 4.65% #23 18
Prev: #5
1.0
-500 -0.4%
P
S
122,500 $13,601,175 2017 Q4 13F Filing 2026-06-30 2026-08-14
EDIT
EDITAS MEDICINE...
Healthcare 1.13% 0.63% #24 7
Prev: #31
3.5
1,934,933 100.4%
P
S
3,861,930 $12,512,653 2026 Q1 13F Filing 2026-06-30 2026-08-14
PTGX
PROTAGONIST THE...
Healthcare 1.11% 1.39% #25 4
Prev: #21
1.4
no change no change
P
S
100,000 $12,258,000 2020 Q4 13F Filing 2026-06-30 2026-08-14
CABA
CABALETTA BIO I...
Healthcare 1.09% 0.49% #26 11
Prev: #37
3.4
2,483,800 180.0%
P
S
3,863,800 $12,016,418 2025 Q3 13F Filing 2026-06-30 2026-08-14
QTTB
Q32 BIO INC
Healthcare 1.07% 1.06% #27 3
Prev: #24
0.4
-325,228 -25.9%
P
S
931,000 $11,860,940 2025 Q4 13F Filing 2026-06-30 2026-08-14
ANNX
ANNEXON INC
Healthcare 0.89% 1.70% #28 10
Prev: #18
0.4
-617,310 -26.5%
P
S
1,714,451 $9,789,515 2025 Q3 13F Filing 2026-06-30 2026-08-14
VSTM
VERASTEM INC
Healthcare 0.62% #29
Prev: #—
3.7
1,800,000
NEW
1,800,000 $6,876,000 2023 Q2 13F Filing 2026-06-30 2026-08-14
ZNTL
ZENTALIS PHARMA...
Healthcare 0.62% 0.44% #30 10
Prev: #40
1.2
no change no change
P
S
1,412,656 $6,851,382 2022 Q4 13F Filing 2026-06-30 2026-08-14
RLMD
RELMADA THERAPE...
Healthcare 0.59% 0.86% #31 5
Prev: #26
1.2
no change no change
P
S
935,000 $6,470,200 2023 Q3 13F Filing 2026-06-30 2026-08-14
OCUL
OCULAR THERAPEU...
Healthcare 0.53% 0.67% #32 3
Prev: #29
1.2
no change no change
P
S
600,000 $5,892,000 2016 Q4 13F Filing 2026-06-30 2026-08-14
TRVI
TREVI THERAPEUT...
Healthcare 0.52% 0.54% #33 2
Prev: #35
0.7
-35,100 -10.2%
P
S
310,000 $5,781,500 2022 Q4 13F Filing 2026-06-30 2026-08-14
BBOT
BRIDGEBIO ONCOL...
Healthcare 0.48% 0.06% #34 18
Prev: #52
3.2
646,718 1213.8%
P
S
700,000 $5,334,000 2026 Q1 13F Filing 2026-06-30 2026-08-14
LYEL
LYELL IMMUNOPHA...
Healthcare 0.44% 0.21% #35 11
Prev: #46
3.2
264,928 334.9%
P
S
344,025 $4,833,551 2024 Q1 13F Filing 2026-06-30 2026-08-14
IRD
OPUS GENETICS I...
Healthcare 0.42% 0.30% #36 7
Prev: #43
0.7
5,000 0.4%
P
S
1,125,000 $4,623,750 2025 Q1 13F Filing 2026-06-30 2026-08-14
FDMT
4D MOLECULAR TH...
Healthcare 0.40% 0.14% #37 12
Prev: #49
3.2
222,146 197.8%
P
S
334,437 $4,448,012 2021 Q4 13F Filing 2026-06-30 2026-08-14
NTLA
INTELLIA THERAP...
Healthcare 0.38% 0.41% #38 3
Prev: #41
0.7
5,000 2.0%
P
S
250,000 $4,230,000 2023 Q2 13F Filing 2026-06-30 2026-08-14
VYGR
VOYAGER THERAPE...
Healthcare 0.38% 0.58% #39 5
Prev: #34
0.7
35,000 3.0%
P
S
1,185,000 $4,147,500 2025 Q4 13F Filing 2026-06-30 2026-08-14
BDSX
BIODESIX INC
Healthcare 0.37% 0.45% #40 2
Prev: #38
0.1
-58,047 -24.4%
P
S
180,000 $4,059,000 2023 Q3 13F Filing 2026-06-30 2026-08-14
RCKT
ROCKET PHARMACE...
Healthcare 0.31% 0.45% #41 2
Prev: #39
0.6
45,000 4.7%
P
S
1,000,000 $3,420,000 2025 Q4 13F Filing 2026-06-30 2026-08-14
JBIO
JADE BIOSCIENCE...
Healthcare 0.29% 0.79% #42 14
Prev: #28
0.1
-282,608 -66.1%
P
S
145,000 $3,221,900 2025 Q4 13F Filing 2026-06-30 2026-08-14
SNWV
SANUWAVE HEALTH...
Healthcare 0.28% 2.23% #43 28
Prev: #15
0.1
-675,127 -68.8%
P
S
306,140 $3,061,400 2025 Q1 13F Filing 2026-06-30 2026-08-14
FBIO
FORTRESS BIOTEC...
Healthcare 0.25% 0.38% #44 2
Prev: #42
0.6
-152,000 -14.6%
P
S
890,000 $2,723,400 2025 Q4 13F Filing 2026-06-30 2026-08-14
DERM
JOURNEY MED COR...
Healthcare 0.22% 0.59% #45 12
Prev: #33
0.1
-610,000 -63.5%
P
S
350,000 $2,478,000 2015 Q2 13F Filing 2026-06-30 2026-08-14
PHAT
PHATHOM PHARMAC...
Healthcare 0.18% #46
Prev: #—
3.6
185,589
NEW
185,589 $2,013,641 2022 Q4 13F Filing 2026-06-30 2026-08-14
INBX
INHIBRX BIOSCIE...
Healthcare 0.17% #47
Prev: #—
3.6
20,291
NEW
20,291 $1,922,572 2022 Q2 13F Filing 2026-06-30 2026-08-14
ENTA
ENANTA PHARMACE...
Healthcare 0.17% 0.21% #48 1
Prev: #47
1.1
no change no change
P
S
125,000 $1,822,500 2016 Q4 13F Filing 2026-06-30 2026-08-14
N/A
HEMAB THERAPEUT...
Unknown 0.16% #49
Prev: #—
3.6
47,652
NEW
47,652 $1,750,258 13F Filing 2026-06-30 2026-08-14
N/A
FIRST TRACKS BI...
Unknown 0.12% #50
Prev: #—
3.5
65,000
NEW
65,000 $1,307,800 13F Filing 2026-06-30 2026-08-14
Showing 1-50 of 67 holdings

Unlock Full Opaleye Management Inc. Analysis

PRO subscribers get access to all historical quarters, Excel/CSV exports, Portfolio Concentration Analytics (PCA), and Risk-Based ENB.

Full Historical Quarters
Excel & CSV Export
PCA & Risk-Based ENB
Auto Cost Basis
Position Change Alerts
Price-Held Analytics
Full history →